Can AI Really Cut Cardiovascular Claims? Investors Demand Proof

The promise of AI in healthcare always brings up futuristic ideas about diagnostics and personalized medicine. For investors, it boils down to something much simpler: can any of these platforms actually bend the cost curve? Can they show measurable reductions in real insurance claims, especially in a high-spend area like cardiovascular care? Lots of AI startups talk about efficiency, but value-based care runs on hard, peer-reviewed evidence of financial performance.

Forget Pilots, Show Me the Claims Data

In healthcare, and especially inside value-based care models, the money follows the data. Technology is just the price of entry, it isn’t enough on its own. Payers and health systems are done with promises of future savings and anecdotal success stories. They want to see strong, public data that shows two things: better patient outcomes and verifiable drops in how much healthcare is used and how much it costs. This is absolutely the case for cardiovascular claims, which are a massive line item for any payer. Many AI companies, for all their new ideas, just don’t have this, falling back on internal pilot studies or surrogate markers. A sharp investor, however, is looking for platforms that have gone through the pain of publishing peer-reviewed claims data, proving they can deliver on the financial side. It’s this data that tells you which AI solutions are actually ready for big, value-based contracts.

Viz.ai: A Clear Case of Claims Reduction

If you’re looking for an AI platform that tangibly cuts cardiovascular claims, Viz.ai is the case study. Its AI-powered synchronized care platform is built for spotting and triaging time-sensitive problems like stroke and pulmonary embolism, and it’s a perfect example of how AI can create economic value by fixing clinical pathways. Viz.ai’s software uses deep learning to read medical images and automatically alert the right care teams, which has been proven to slash the time from symptom to treatment. For example, one study showed that Viz.ai’s automated detection of suspected large vessel occlusion (LVO) strokes cut door-to-puncture times by an average of 86.7 minutes (dropping from 206.6 to 119.9 minutes). Another study found a 53% reduction in that same metric when Viz.ai was paired with Pulsara. Getting to a stroke patient faster directly leads to better outcomes, including less disability and shorter hospital stays. The financial impact is obvious. A less severe stroke means fewer days in the ICU, less need for expensive long-term rehab, and in the end, a much smaller final bill. While the exact percentage of claims reduction will differ between hospital systems, the mechanism is straightforward: by tightening up the clinical pathway and improving acute care, Viz.ai’s platform lowers the total cost of care. For instance, the Viz PE Solution has demonstrated a 74% reduction in in-hospital mortality rates for pulmonary embolism. And the Viz Connect platform has been shown to increase overall cardiac monitoring 1.3 times and guideline-driven cardiac monitoring 8.4 times in post-stroke patients, dramatically cutting the time to device placement (like a 97% decrease for Insertable Cardiac Monitors). This isn’t just about being more efficient. It’s about stopping costly complications before they ever start.

The Rest of the Field: Data vs. Admin Costs

Beyond Viz.ai, most of the health AI world is still struggling to prove its financial worth. Take a company like Tempus AI. While they’re famous for precision oncology, they’re moving into cardiology by building out complete data profiles. Tempus’s strategy is to pool huge amounts of clinical and genomic data to personalize treatment and maybe spot at-risk people earlier, which would theoretically cut down on future cardiovascular claims. The investor appetite for this kind of data-moat strategy is huge, Tempus AI went public on Nasdaq (ticker “TEM”) on June 14, 2024, raising $410.7 million in its IPO at a $6.1 billion valuation. As of September 2026, its market cap is around $11.37 billion USD. Tempus AI IPO prospectus. Another way AI is trying to prove its economic value is by tackling administrative and triage costs. Hippocratic AI, a safety-focused large language model (LLM), is going after this space. Backed by big names like Avenir Growth, CapitalG (Google’s growth fund), General Catalyst, and Andreessen Horowitz, Hippocratic AI raised a $126 million Series C in November 2025 at a $3.5 billion valuation, for a total of $404 million in funding. The company wants to automate routine admin work and handle initial patient chats. These platforms aren’t directly intervening to stop a heart attack, but by making hospital operations smoother and cutting down on human error during intake, they can free up money and people for more critical work. An AI-native company like Hippocratic AI that can manage patient flow and paperwork well can create a ripple effect on how resources are used, which eventually hits the bottom line.

Investor Checklist: What Actually Matters

For investors, the takeaway is simple: focus on AI platforms with peer-reviewed proof that they reduce actual cardiovascular insurance claims. Don’t get distracted by pilot studies or slick projections. The gap between a cool technology and a financially sound business is closed by empirical validation. When you’re looking at a potential investment, what should you ask?

• Peer-Reviewed Claims Data: Where’s the published data? I want to see studies in real journals showing lower ICU days or readmissions because of this tech.
• Reimbursement Pathways: How does it get paid for? Does it have CPT codes or other reimbursement deals that prove its value to payers? Anumana is making real progress here as the first ECG-AI with its own Category III CPT codes (0764T and 0765T) issued in 2023. The Centers for Medicare & Medicaid Services (CMS) also added Anumana’s low ejection fraction ECG-AI tech to its 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule for reimbursement. AMA CPT code updates for AI.
• Scalability and Integration: Can this solution plug into existing hospital workflows without a massive IT project? Can it be adopted widely enough to actually make a dent in claims?
• Regulatory Compliance: What’s the regulatory story? Is the platform built with GMLP principles, a strong QMS (ISO 13485), and a clear FDA pathway (510(k) or De Novo) that de-risks the commercial plan?

The value-based care AI field is maturing. New ideas are essential, but the financial reality of healthcare means the focus must be on platforms that prove their worth with real economic outcomes. Data and technology are necessary, but without hard evidence of claims reduction, they are insufficient for participating in value-based care. The future of cardiovascular AI investment belongs to companies that can show, without a doubt, that they bend the cost curve.